The abstract is read at the publisher; the summary is JClub's.
In biliary tract cancer patients, rising EGFR and MET CNV scores during first-line systemic anti-cancer treatment predict worse time to progression and overall survival.
- Why it matters: Longitudinal molecular change during first-line systemic treatment is poorly characterized in biliary tract cancers, limiting understanding of resistance mechanisms and non-invasive monitoring.
- What they did: Plasma was collected at baseline (N=39) and progressive disease (N=30) for ctDNA NGS (SNV/CNV) and matched CT radiomics, alongside total tumor burden (TTB) and exploratory radiomic feature analyses.
- The result: Increasing EGFR CNV score showed shorter TTP (4.1 vs 9.5 months, p=0.003) and worse OS (10.1 vs 21.6 months, p=0.02), and increasing MET CNV score showed shorter TTP (4.2 vs 10.1 months, p=0.01) and worse OS (9.5 vs 20.2 months, p=0.06).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.